← Back to patent-cliff list
TRV-120027
Tier C — Watch / tradeTRV-120027
Trevena Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT1
Indications (approved)：冠状病毒感染, COVID-19, Acute decompensated heart failure, Kidney disease, Heart failure
Regional status
US
Phase III
2021-07-15
EU
No progress
2010-12-01
China
-
Japan
-
Synthetic routes & intermediates3 routes
Originator routes × 0Optimised (non-patent) × 3Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OptimisedRoute 1Steps 4 · Total yield /
(I)692039-1-a13734-41-3(II)692039-1-a98807-40-0(III)692039-1-a60-18-4(IV)692039-1-a77456-95-2(V)692039-1-a1824712-61-9(VI)692039-1-a73-32-5(VII)692039-1-a1824712-60-8(VIII)692039-1-a,(VIII)692039-1-b1824712-65-3(IX)692039-1-a—(X)692039-1-a,(X)692039-1-b1824712-59-5(XI)692039-1-a1824712-69-7(XII)692039-1-a1824712-70-0API · TRV-120027
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)692039-1-a | 13734-41-3 | (S)-2-((tert-Butoxycarbonyl)amino)-3-methylbutanoic acid |
| (II)692039-1-a | 98807-40-0 | Ethoxycarbonyl N-(tert-butoxycarbonyl)-L-valinate |
| (III)692039-1-a | 60-18-4 | (-)-alpha-Amino-p-hydroxyhydrocinnamic acid |
| (IV)692039-1-a | 77456-95-2 | N-(tert-Butoxycarbonyl)-L-valyl-L-tyrosine |
| (V)692039-1-a | 1824712-61-9 | Ethoxycarbonyl N-(tert-butoxycarbonyl)-L-valyl-L-tyrosinate |
| (VI)692039-1-a | 73-32-5 | (2S,3S)-alpha-Amino-beta-merthylvaleric acid |
| (VII)692039-1-a | 1824712-60-8 | N-(tert-Butoxycarbonyl)-L-valyl-L-tyrosyl-L-isoleucine |
| (VIII)692039-1-a,(VIII)692039-1-b | 1824712-65-3 | Benzyl L-histidyl-L-prolyl-D-alaninate hydrochloride |
| (IX)692039-1-a | - | Benzyl L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-D-alaninate hydrochloride |
| (X)692039-1-a,(X)692039-1-b | 1824712-59-5 | N-[(Benzyloxy)carbonyl]-N-methylglycyl-L-arginine |
| (XI)692039-1-a | 1824712-69-7 | Benzyl N-[(benzyloxy)carbonyl]-N-methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-D-alaninate hydrochloride |
| (XII)692039-1-a | 1824712-70-0 | N-Methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-D-alanine acetate |
OptimisedRoute 2Steps 4 · Total yield /
(VIII)692039-1-a,(VIII)692039-1-b1824712-65-3(X)692039-1-a,(X)692039-1-b1824712-59-5(XIII)692039-1-b15761-39-4(XIV)692039-1-b1392268-76-6(XIX)692039-1-b39608-31-6(XV)692039-1-b41036-32-2(XVI)692039-1-b1824712-63-1(XVII)692039-1-b17791-52-5(XVIII)692039-1-b1824712-66-4(XX)692039-1-b14533-84-7(XXI)692039-1-b80909-58-6(XXII)692039-1-b74-79-3API · TRV-120027
| Code | CAS No. | Intermediate |
|---|---|---|
| (VIII)692039-1-a,(VIII)692039-1-b | 1824712-65-3 | Benzyl L-histidyl-L-prolyl-D-alaninate hydrochloride |
| (X)692039-1-a,(X)692039-1-b | 1824712-59-5 | N-[(Benzyloxy)carbonyl]-N-methylglycyl-L-arginine |
| (XIII)692039-1-b | 15761-39-4 | (2S)-1-[(2-Methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid |
| (XIV)692039-1-b | 1392268-76-6 | Ethoxycarbonyl 1-(tert-butoxycarbonyl)-L-prolinate |
| (XIX)692039-1-b | 39608-31-6 | 2-{[(Benzyloxy)carbonyl](methyl)amino}acetic acid |
| (XV)692039-1-b | 41036-32-2 | Benzyl D-alaninate 4-methylbenzenesulfonate |
| (XVI)692039-1-b | 1824712-63-1 | Benzyl L-prolyl-D-alaninate hydrochloride |
| (XVII)692039-1-b | 17791-52-5 | (2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(1H-imidazol-5-yl)propanoic acid |
| (XVIII)692039-1-b | 1824712-66-4 | Benzyl N-(tert-butoxycarbonyl)-L-histidyl-L-prolyl-D-alaninate |
| (XX)692039-1-b | 14533-84-7 | Pentafluorophenyl trifluoroacetate |
| (XXI)692039-1-b | 80909-58-6 | Pentafluorophenyl N-[(benzyloxy)carbonyl]-N-methylglycinate |
| (XXII)692039-1-b | 74-79-3 | (S)-(+)-Arginine |
OptimisedRoute 3Steps 4 · Total yield /
(I)692039-2-a80909-58-6(II)692039-2-a2149-70-4(III)692039-2-a364636-02-2(IV)692039-2-a1824712-62-0(V)692039-2-a1824712-60-8(VI)692039-2-a1824712-71-1(VII)692039-2-a1824712-65-3(VIII)692039-2-a1824712-72-2API · TRV-120027
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)692039-2-a | 80909-58-6 | Pentafluorophenyl N-[(benzyloxy)carbonyl]-N-methylglycinate |
| (II)692039-2-a | 2149-70-4 | N5-(N-Nitrocarbamimidoyl)-L-ornithine |
| (III)692039-2-a | 364636-02-2 | N-[(Benzyloxy)carbonyl]-N-methylglycyl-N5-(N-nitrocarbamimidoyl)-L-ornithine |
| (IV)692039-2-a | 1824712-62-0 | L-Valyl-L-tyrosyl-L-isoleucine hydrochloride |
| (V)692039-2-a | 1824712-60-8 | N-(tert-Butoxycarbonyl)-L-valyl-L-tyrosyl-L-isoleucine |
| (VI)692039-2-a | 1824712-71-1 | N-[(Benzyloxy)carbonyl]-N-methylglycyl-N5-(N-nitrocarbamimidoyl)-L-ornithyl-L-valyl-L-tyrosyl-L-isoleucine |
| (VII)692039-2-a | 1824712-65-3 | Benzyl L-histidyl-L-prolyl-D-alaninate hydrochloride |
| (VIII)692039-2-a | 1824712-72-2 | Benzyl N-[(benzyloxy)carbonyl]-N-methylglycyl-N5-(N-nitrocarbamimidoyl)-L-ornithyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-D-alaninate |
Frequently asked questions
What are the approved indications of TRV-120027?
Approved indications include: 冠状病毒感染, COVID-19, Acute decompensated heart failure, Kidney disease, Heart failure.
When does the TRV-120027 patent expire?
No public expiry year is available for TRV-120027 yet; this page updates once verified.
How many synthesis routes are recorded for TRV-120027?
3 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy TRV-120027 intermediates?
All intermediates in TRV-120027 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for TRV-120027 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06